Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2026-02-04 00:00:00 ET · period of report 2026-02-02 · accession 0001628280-26-005566 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-04 | 2026-02-02 | ARQT | Edwards Larry Todd | See Remarks | S - Sale | $25.50 | -2,052 | 148.9K | -1% | -$52.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-02 | S | D | 2,052 | $25.50 | 148,865 | D | — | — | (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F3) Includes 724 shares purchased under the Issuer's Employee Stock Purchase Plan on November 30, 2025. |